@article{576d257324be4f178f67bd0a19b36111,
title = "Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection",
abstract = "Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants and young children worldwide. Here we evaluated host demographic and viral factors associated with RSV disease severity in 325 RSV-infected infants under 1 year of age from 3 European countries during 2017–2020. Younger infants had a higher clinical severity (ReSViNET) score and were more likely to require hospitalization, intensive care, respiratory support, and/or mechanical ventilation than older infants (,3 months vs 3 to,6 months and 3 to,6 months vs ≥6 months). Older age (≥6 months vs,3 months), higher viral load, and RSV-A were associated with a greater probability of fever. RSV-A and RSV-B caused similar disease severity and had similar viral dynamics. Infants with a more severe RSV infection, demonstrated by having a higher ReSViNET score, fever, and requiring hospitalization and intensive care, were more likely to have developed subsequent wheezing at 1 year of age.",
keywords = "Hospitalization, Humans, Infant, Respiratory Sounds/etiology, Respiratory Syncytial Virus Infections/complications, Respiratory Syncytial Virus, Human, Severity of Illness Index, disease severity, respiratory syncytial virus, subgroup, viral load, wheezing",
author = "McGinley, \{Joseph P.\} and Lin, \{Gu Lung\} and Deniz {\"O}ner and Tanya Golubchik and Daniel O'Connor and Snape, \{Matthew D.\} and Olivier Gruselle and Langedijk, \{Annefleur C.\} and Joanne Wildenbeest and Peter Openshaw and Harish Nair and Jeroen Aerssens and Louis Bont and Federico Martin{\'o}n-Torres and Drysdale, \{Simon B.\} and Pollard, \{Andrew J.\}",
note = "Funding Information: This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; the NIHR Thames Valley and South Midlands Clinical Research Network; the British Research Council; and the Respiratory Syncytial Virus Consortium in Europe (RESCEU) project. RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant number 116019). This Joint Undertaking receives support from the European Union Horizon 2020 Research and Innovation Program and European Federation of Pharmaceutical Industries and Associations. Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.",
year = "2022",
month = aug,
day = "1",
doi = "10.1093/infdis/jiac163",
language = "English",
volume = "226",
pages = "S45--S54",
journal = "The Journal of infectious diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "Supplement\_1",
}